Researchers at LSTM and Imperial College London have designed drugs which could help combat any potential new flu pandemic, by targeting the receptors of the cells by which the virus gains entry to the human body.
In a paper published today(link is external) in the Journal of Immunology the team, led by LSTM’s Professor Richard Pleass, show that by engineering a part of an antibody they can target the viral proteins that allow flu to mutate and become so deadly to humans.
Last year marked the centenary of the 1918 influenza pandemic that claimed nearly 100 million lives worldwide, thus becoming the deadliest disease outbreak in recorded history. Global annual influenza outbreaks account for 300,000-650,000 respiratory deaths, mostly in children and the elderly.
Professor Pleass explained: “Influenza vaccines have limited public health impact during pandemics, and current influenza vaccines are less efficacious than vaccines for many other infectious diseases. This is because influenza viruses that circulate in human and animal populations mutate two key viral surface proteins, haemagglutinin (HA) and neuraminidase (NA), thus allowing them to escape from protective antibodies produced through natural infection or vaccination”
Both HA and NA target a sugar called sialic acid, that is found in abundance on the receptors of cells lining the mammalian respiratory tract, which the virus uses to gain entry into the body. The sialic acid-binding contacts on HA and NA do not mutate readily, otherwise the virus would not be able to infect human cells.
The team has engineered antibody Fc fragments with enhanced sialic acid that target these conserved parts of both HA and NA, binding influenza viruses and thus blocking their interactions with human cells.
By targeting sialic acid, these engineered biologicals may also be useful in the control of other pathogens, such as group B streptococci, Streptococcus pneumoniae, Mycoplasma genitalium, and Newcastle Disease Virus.
“Better anti-influenza therapeutics are urgently needed.” Continued Professor Pleass: “The transfer of antibodies from people recovering from influenza during the 1918 and 2009 pandemics reduced mortality from influenza by 50% and 26% respectively. However, to be useful, these antibody medicines (also called FLU-IVIG) need to be manufactured in advance of future epidemics, which is obviously problematic as there may be modest or little neutralising activity against newly emerging strains. Therefore, combinations of existing medicines, including FLU-IVIG, with sialic acid blockers could increase their efficacy while future-proofing against the next pandemic.”
Professor Sara Marshall, Head of Clinical and Physiological Sciences at the Wellcome Trust, who provided funding for this work, said: “This is a fascinating project, and one which could have really far-reaching impact not only for influenza but as a platform technology to develop new medicines for many other diseases that are currently treated by antibodies.”
The technology described is available for licensing.
The Latest on: Anti-influenza drugs
via Google News
The Latest on: Anti-influenza drugs
- China Endorses Avigan/Favipiravir Drug For Coronavirus Treatmenton March 18, 2020 at 10:23 am
China's health leadership have announced they have found the Japanese-developed anti-influenza drug, Avigan, to be effective in treating coronavirus patients. Zhang Xinmin, China’s director of the ...
- Favipiravir endorsed as anti-viral drug for Coronaviruson March 18, 2020 at 9:55 am
Favipiravir (also known as Avigan), a Japanese-developed anti-influenza drug has been endorsed by China’s health leadership as an anti-viral drug for Coronavirus. Based on results of clinical trials ...
- What is Favipiravir and will the Drug Help to Halt the COVID-19 Pandemic?on March 18, 2020 at 7:47 am
After China announced encouraging results with the drug Favipiravir, in the fight against the coronavirus, the spotlight turned to it. What do we know about this medicine so far? Favipiravir was ...
- Drug being used to treat flu in Japan is 'clearly effective', Chinese officials sayon March 18, 2020 at 3:42 am
Trials of the Avigan anti-influenza drug in Shenzhen proved successful in reducing the duration of the disease in patients, according to Chinese officials The drug is manufactured by a subsidiary ...
- China to use anti-flu drug Avigan to treat viruson March 18, 2020 at 12:32 am
The Chinese government says it has officially decided to use the Japanese-developed anti-influenza drug Avigan in treating people infected with the new coronavirus. Zhang Xinmin, director of the ...
- Repurposed drugs may help scientists fight the new coronaviruson March 10, 2020 at 4:02 am
Yet a few anecdotal accounts suggest the HIV drugs may help people with COVID-19 recover. Doctors at Rajavithi Hospital in Bangkok reported in a press briefing February 2 that they had treated a ...
- Scientists in Japan rush to analyze existing drugs for COVID-19 treatmenton March 3, 2020 at 12:04 am
Japan's health minister, Katsunobu Kato, said in late February, the country is considering using Avigan, an anti-influenza medication, to treat the novel coronavirus. An HIV drug has also been ...
- Fujifilm Jumps 5% as Japan Plans to Recommend Its Drug for Coronavirus Treatmenton February 23, 2020 at 4:00 pm
Avigan is an anti-influenza drug developed by a Fujifilm group company that has previously been used to treat Ebola, Fujifilm said on its website. Citing Kato, Bloomberg said test dosages have ...
- Gov't considers using anti-flu drug Avigan to treat coronaviruson February 22, 2020 at 8:01 am
Avigan, developed by Fujifilm Toyama Chemical Co, has been manufactured and stocked in Japan as an anti-influenza drug, but it is hoped that it can help treat other diseases, including Ebola, as well ...
- Japan weighs using anti-flu drug Avigan to treat Covid-19 patientson February 21, 2020 at 4:00 pm
Avigan is an anti-influenza drug developed by Fujifilm Toyama Chemical Co., but it is hoped that it can also help treat other diseases, including Ebola, as well as a tick-borne illness.
via Bing News